<DOC>
	<DOC>NCT02689245</DOC>
	<brief_summary>Data for stool microbiome will be collected for all the chronic hepatitis B subjects (pre cirrhotic,compensated,decompensated and reactivation). All the in and out patient with Hepatitis B reactivation will be recruited and randomized into two arms. Group 1 Tenofovir Group 2 Tenofovir with FMT (Fecal Microbiota Transplant). Tenofovir would be given 300 mg once daily FMT through NJ (Naso-Jejunal) tube for 7 days.</brief_summary>
	<brief_title>Randomized Controlled Trial Comparing the Efficacy and Safety of FMT in Hepatitis B Reactivation Leads to Acute on Chronic Liver Failure.</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1. Reactivation of Chronic Hepatitis B Virus leads to Acute on Chronic Liver Failure (MELD (Model for End Stage liver Disease) &gt;18 years. 2. 1875 yr both male and female 3. Chronic Hepatitis B patient (precirrhotic,compensated,decompensated). 4. Healthy adult family member of the patient will be taken as a control. Acute on Chronic Liver Failure due to other causes Alcohol,Hepatitis A Virus,Hepatitis E Virus,HSV (Herpes Simplex Virus),CMV (Cytomegalovirus),EBV (EpsteinBarr Virus) other hepatotropic virus,Drugs,CAM. Active gastrointestinal bleeding Intracranial bleeding Multiorgan failure (&gt;2) on mechanical ventilation SOFA score &gt;2 On high inotropic support Paralytic ileus Pregnancy Hepatocellular Carcinoma Antibiotic,probiotic within last 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>